These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 25829023)

  • 1. Oral cyclosporine A treatment is feasible after myeloablative conditioning in allogeneic hematopoietic stem cell transplantation.
    Nygaard M; Hovgaard D; Schjødt IM; Andersen NS; Vindeløv L; Sengeløv H
    J Clin Pharm Ther; 2015 Jun; 40(3):358-61. PubMed ID: 25829023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of cyclosporine A at a high-peak concentration of twice-daily infusion and oral administration in allogeneic haematopoietic stem cell transplantation.
    Inoue Y; Saito T; Ogawa K; Nishio Y; Kosugi S; Suzuki Y; Shibuya Y; Kato M; Takahashi M; Miura I
    J Clin Pharm Ther; 2011 Aug; 36(4):518-24. PubMed ID: 21105879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of cyclosporine A concentration on acute graft-vs-host disease incidence after haploidentical hematopoietic cell transplantation.
    Stocker N; Duléry R; Battipaglia G; Brissot E; Médiavilla C; Sestili S; Paviglianiti A; Ledraa T; Mohty R; Bazarbachi A; Belhocine R; Vekhoff A; Ruggeri A; Mohty M; Malard F
    Eur J Haematol; 2019 Jul; 103(1):10-17. PubMed ID: 30958904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation.
    Malard F; Szydlo RM; Brissot E; Chevallier P; Guillaume T; Delaunay J; Ayari S; Dubruille V; Le Gouill S; Mahe B; Gastinne T; Blin N; Saulquin B; Harousseau JL; Moreau P; Mohty M
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):28-34. PubMed ID: 20053329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporine levels > 195 μg/L on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Bianchi M; Heim D; Lengerke C; Halter J; Gerull S; Kleber M; Tsakiris DA; Passweg J; Tzankov A; Medinger M
    Ann Hematol; 2019 Apr; 98(4):971-977. PubMed ID: 30542943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.
    Barkholt L; Remberger M; Bodegård H; Ringdén O; Böttiger Y
    Bone Marrow Transplant; 2007 Oct; 40(7):683-9. PubMed ID: 17660840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achievement of target cyclosporine concentrations as a predictor of severe acute graft versus host disease in children undergoing hematopoietic stem cell transplantation and receiving cyclosporine and methotrexate prophylaxis.
    Punnett A; Sung L; Price V; Das P; Diezi M; Doyle J; Dupuis LL
    Ther Drug Monit; 2007 Dec; 29(6):750-7. PubMed ID: 18043472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of cyclophosphamide on serum cyclosporine levels at the conditioning of hematopoietic stem cell transplantation.
    Nagamura F; Takahashi T; Takeuchi M; Iseki T; Ooi J; Tomonari A; Uchimaru K; Takahashi S; Tojo A; Tani K; Asano S
    Bone Marrow Transplant; 2003 Dec; 32(11):1051-8. PubMed ID: 14625575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and efficacy of acute graft-versus-host disease prophylaxis with a higher target blood concentration of cyclosporine around 500 ng/mL.
    Machishima T; Kako S; Wada H; Yamasaki R; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Ashizawa M; Terasako K; Kimura S; Kikuchi M; Nakasone H; Kanda J; Yamazaki R; Nishida J; Kanda Y
    Clin Transplant; 2013; 27(5):749-56. PubMed ID: 24033855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of cyclosporine initiation time on the outcome of matched allogeneic stem-cell transplantation following fludarabine-based conditioning.
    Kedmi M; Dray L; Grisariu S; Resnick IB; Stepensky P; Aker M; Or R; Shapira MY
    Transpl Int; 2012 Dec; 25(12):1241-7. PubMed ID: 22974004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited sampling strategies for estimating intravenous and oral cyclosporine area under the curve in pediatric hematopoietic stem cell transplantation.
    Sarem S; Nekka F; Barrière O; Bittencourt H; Duval M; Teira P; Haddad E; Théorêt Y; Lapeyraque AL; Litalien C
    Ther Drug Monit; 2015 Apr; 37(2):198-205. PubMed ID: 25162214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level.
    Oshima K; Kanda Y; Nakasone H; Arai S; Nishimoto N; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
    Am J Hematol; 2008 Mar; 83(3):226-32. PubMed ID: 17918253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
    Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH
    Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.
    Hamad N; Shanavas M; Michelis FV; Uhm J; Gupta V; Seftel M; Kuruvilla J; Lipton JH; Messner HA; Kim DD
    Am J Hematol; 2015 May; 90(5):392-9. PubMed ID: 25615933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation.
    de Kort EA; de Lil HS; Bremmers MEJ; van Groningen LFJ; Blijlevens NMA; Huls G; Brüggemann RJM; van Dorp S; van der Velden WJFM
    PLoS One; 2019; 14(3):e0213913. PubMed ID: 30897127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of blood cyclosporine concentration on the outcome of hematopoietic stem cell transplantation from an HLA-matched sibling donor.
    Kanda Y; Hyo R; Yamashita T; Fujimaki K; Oshima K; Onoda M; Mori T; Sakura T; Tanaka M; Sakai M; Taguchi J; Kurakawa M; Maruta A; Okamoto S; Sakamaki H;
    Am J Hematol; 2006 Nov; 81(11):838-44. PubMed ID: 16888784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Converting cyclosporine A from intravenous to oral administration in hematopoietic stem cell transplant recipients and the role of azole antifungals.
    Atiq F; Hameli E; Broers AEC; Doorduijn JK; Van Gelder T; Andrews LM; Koch BCP; Versmissen J; de Winter BCM
    Eur J Clin Pharmacol; 2018 Jun; 74(6):767-773. PubMed ID: 29500599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of cyclosporine levels on the development of acute graft versus host disease after reduced intensity conditioning allogeneic stem cell transplantation.
    García Cadenas I; Valcarcel D; Martino R; Piñana JL; Barba P; Novelli S; Esquirol A; Garrido A; Saavedra S; Granell M; Moreno C; Briones J; Brunet S; Sierra J
    Mediators Inflamm; 2014; 2014():620682. PubMed ID: 24623962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
    Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
    Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.